Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.
2 reports, 1 independent
Updated Aug 27
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Monopar Therapeutics received research reports and ratings from Cantor Fitzgerald and Morgan Stanley.1 source
Analyst ratings published on MarketBeat for Monopar Therapeutics.1 source
Keep exploring
The entities involved
-
MarketBeat
American personal finance blog
-
Monopar Therapeutics
biopharmaceutical company
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
Related events
- Analyst reports published on MarketBeat regarding Tantech, a company whose stock trades on the Nasdaq stock exchange.
- ProKidney and Cartesian Therapeutics were listed on the Nasdaq stock exchange and received ratings from MarketBeat.
- MarketBeat reported on the stock performance of Allarity Therapeutics, Inc. on September 1, 2026.
- MarketBeat provides stock rating data for Vivos Therapeutics, which is listed on Nasdaq.
- MarketBeat reported the stock average rating for Range Capital Acquisition Corp., a company that trades on the Nasdaq exchange.